abstract |
The present invention discloses antibody molecules that specifically bind to PD-L1. The invention also discloses combination therapies comprising such anti-PD-L1 antibody molecules. The anti-PD-L1 antibody molecules are useful for the treatment, prevention, and/or diagnosis of cancerous or infectious conditions and conditions. |